Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more
Johnson & Johnson (JNJ) - Net Assets
Latest net assets as of September 2025: $79.28 Billion USD
Based on the latest financial reports, Johnson & Johnson (JNJ) has net assets worth $79.28 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($192.82 Billion) and total liabilities ($113.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $79.28 Billion |
| % of Total Assets | 41.12% |
| Annual Growth Rate | 8.16% |
| 5-Year Change | 12.98% |
| 10-Year Change | 0.48% |
| Growth Volatility | 11.6 |
Johnson & Johnson - Net Assets Trend (1985–2024)
This chart illustrates how Johnson & Johnson's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Johnson & Johnson (1985–2024)
The table below shows the annual net assets of Johnson & Johnson from 1985 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $71.49 Billion | +3.95% |
| 2023-12-31 | $68.77 Billion | -10.46% |
| 2022-12-31 | $76.80 Billion | +3.76% |
| 2021-12-31 | $74.02 Billion | +16.98% |
| 2020-12-31 | $63.28 Billion | +6.40% |
| 2019-12-31 | $59.47 Billion | -0.47% |
| 2018-12-31 | $59.75 Billion | -0.68% |
| 2017-12-31 | $60.16 Billion | -14.57% |
| 2016-12-31 | $70.42 Billion | -1.03% |
| 2015-12-31 | $71.15 Billion | +3.13% |
| 2014-12-31 | $68.99 Billion | -6.84% |
| 2013-12-31 | $74.05 Billion | +14.23% |
| 2012-12-31 | $64.83 Billion | +13.57% |
| 2011-12-31 | $57.08 Billion | +0.89% |
| 2010-12-31 | $56.58 Billion | +11.84% |
| 2009-12-31 | $50.59 Billion | +19.00% |
| 2008-12-31 | $42.51 Billion | -1.87% |
| 2007-12-31 | $43.32 Billion | +10.18% |
| 2006-12-31 | $39.32 Billion | +1.57% |
| 2005-12-31 | $38.71 Billion | +21.68% |
| 2004-12-31 | $31.81 Billion | +18.40% |
| 2003-12-31 | $26.87 Billion | +18.38% |
| 2002-12-31 | $22.70 Billion | -6.34% |
| 2001-12-31 | $24.23 Billion | +18.82% |
| 2000-12-31 | $20.39 Billion | +25.79% |
| 1999-12-31 | $16.21 Billion | +15.17% |
| 1998-12-31 | $14.08 Billion | +13.90% |
| 1997-12-31 | $12.36 Billion | +14.06% |
| 1996-12-31 | $10.84 Billion | +19.80% |
| 1995-12-31 | $9.04 Billion | +27.00% |
| 1994-12-31 | $7.12 Billion | +27.91% |
| 1993-12-31 | $5.57 Billion | +7.68% |
| 1992-12-31 | $5.17 Billion | -8.09% |
| 1991-12-31 | $5.63 Billion | +14.82% |
| 1990-12-31 | $4.90 Billion | +18.13% |
| 1989-12-31 | $4.15 Billion | +18.41% |
| 1988-12-31 | $3.50 Billion | +0.52% |
| 1987-12-31 | $3.48 Billion | +23.40% |
| 1986-12-31 | $2.82 Billion | -15.72% |
| 1985-12-31 | $3.35 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Johnson & Johnson's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4351.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $155.79 Billion | 217.92% |
| Common Stock | $3.12 Billion | 4.36% |
| Other Comprehensive Income | $-11.74 Billion | -16.42% |
| Total Equity | $71.49 Billion | 100.00% |
Johnson & Johnson Competitors by Market Cap
The table below lists competitors of Johnson & Johnson ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Exxon Mobil Corp
NYSE:XOM
|
$637.68 Billion |
|
JPMorgan Chase & Co
NYSE:JPM
|
$769.68 Billion |
|
Eli Lilly and Company
NYSE:LLY
|
$830.88 Billion |
|
Berkshire Hathaway Inc
NYSE:BRK-A
|
$912.15 Billion |
|
Walmart Inc. Common Stock
NASDAQ:WMT
|
$546.27 Billion |
|
Visa Inc. Cl A
LSE:0QZ0
|
$537.58 Billion |
|
Visa Inc. Class A
NYSE:V
|
$536.66 Billion |
|
ASML HOLDING NY EO-09
F:ASMF
|
$473.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Johnson & Johnson's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 68,774,000,000 to 71,490,000,000, a change of 2,716,000,000 (3.9%).
- Net income of 14,066,000,000 contributed positively to equity growth.
- Dividend payments of 11,823,000,000 reduced retained earnings.
- Share repurchases of 2,432,000,000 reduced equity.
- Other comprehensive income increased equity by 786,000,000.
- Other factors increased equity by 2,119,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $14.07 Billion | +19.68% |
| Dividends Paid | $11.82 Billion | -16.54% |
| Share Repurchases | $2.43 Billion | -3.4% |
| Other Comprehensive Income | $786.00 Million | +1.1% |
| Other Changes | $2.12 Billion | +2.96% |
| Total Change | $- | 3.95% |
Book Value vs Market Value Analysis
This analysis compares Johnson & Johnson's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 207.66x to 8.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.15 | $238.11 | x |
| 1986-12-31 | $1.03 | $238.11 | x |
| 1987-12-31 | $1.28 | $238.11 | x |
| 1988-12-31 | $1.26 | $238.11 | x |
| 1989-12-31 | $1.53 | $238.11 | x |
| 1990-12-31 | $1.82 | $238.11 | x |
| 1991-12-31 | $2.08 | $238.11 | x |
| 1992-12-31 | $1.97 | $238.11 | x |
| 1993-12-31 | $2.12 | $238.11 | x |
| 1994-12-31 | $2.73 | $238.11 | x |
| 1995-12-31 | $3.50 | $238.11 | x |
| 1996-12-31 | $3.97 | $238.11 | x |
| 1997-12-31 | $4.51 | $238.11 | x |
| 1998-12-31 | $4.97 | $238.11 | x |
| 1999-12-31 | $5.27 | $238.11 | x |
| 2000-12-31 | $6.58 | $238.11 | x |
| 2001-12-31 | $7.87 | $238.11 | x |
| 2002-12-31 | $7.43 | $238.11 | x |
| 2003-12-31 | $8.55 | $238.11 | x |
| 2004-12-31 | $10.66 | $238.11 | x |
| 2005-12-31 | $12.89 | $238.11 | x |
| 2006-12-31 | $13.27 | $238.11 | x |
| 2007-12-31 | $14.88 | $238.11 | x |
| 2008-12-31 | $14.99 | $238.11 | x |
| 2009-12-31 | $18.14 | $238.11 | x |
| 2010-12-31 | $20.29 | $238.11 | x |
| 2011-12-31 | $20.57 | $238.11 | x |
| 2012-12-31 | $23.05 | $238.11 | x |
| 2013-12-31 | $25.74 | $238.11 | x |
| 2014-12-31 | $24.36 | $238.11 | x |
| 2015-12-31 | $25.29 | $238.11 | x |
| 2016-12-31 | $25.25 | $238.11 | x |
| 2017-12-31 | $21.91 | $238.11 | x |
| 2018-12-31 | $21.90 | $238.11 | x |
| 2019-12-31 | $22.16 | $238.11 | x |
| 2020-12-31 | $23.69 | $238.11 | x |
| 2021-12-31 | $27.68 | $238.11 | x |
| 2022-12-31 | $28.83 | $238.11 | x |
| 2023-12-31 | $26.86 | $238.11 | x |
| 2024-12-31 | $29.43 | $238.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Johnson & Johnson utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.68%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.84%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 2.52x
- Recent ROE (19.68%) is below the historical average (24.26%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 18.31% | 9.56% | 1.26x | 1.52x | $278.61 Million |
| 1986 | 11.67% | 4.71% | 1.19x | 2.08x | $47.08 Million |
| 1987 | 23.90% | 10.40% | 1.22x | 1.88x | $484.50 Million |
| 1988 | 27.80% | 10.82% | 1.26x | 2.03x | $623.70 Million |
| 1989 | 26.08% | 11.09% | 1.23x | 1.91x | $667.20 Million |
| 1990 | 23.33% | 10.18% | 1.18x | 1.94x | $653.00 Million |
| 1991 | 25.97% | 11.74% | 1.18x | 1.87x | $898.40 Million |
| 1992 | 19.92% | 7.49% | 1.16x | 2.30x | $512.90 Million |
| 1993 | 32.09% | 12.64% | 1.15x | 2.20x | $1.23 Billion |
| 1994 | 28.17% | 12.75% | 1.00x | 2.20x | $1.29 Billion |
| 1995 | 26.57% | 12.75% | 1.05x | 1.98x | $1.50 Billion |
| 1996 | 26.64% | 13.35% | 1.08x | 1.85x | $1.80 Billion |
| 1997 | 26.73% | 14.60% | 1.05x | 1.74x | $2.07 Billion |
| 1998 | 21.33% | 12.52% | 0.88x | 1.94x | $1.60 Billion |
| 1999 | 26.36% | 15.26% | 0.96x | 1.80x | $2.65 Billion |
| 2000 | 24.29% | 16.98% | 0.85x | 1.68x | $2.91 Billion |
| 2001 | 23.39% | 17.54% | 0.84x | 1.59x | $3.24 Billion |
| 2002 | 29.07% | 18.17% | 0.90x | 1.79x | $4.33 Billion |
| 2003 | 26.79% | 17.19% | 0.87x | 1.80x | $4.51 Billion |
| 2004 | 25.71% | 17.28% | 0.89x | 1.68x | $5.00 Billion |
| 2005 | 25.99% | 19.92% | 0.86x | 1.52x | $6.19 Billion |
| 2006 | 28.11% | 20.73% | 0.76x | 1.79x | $7.12 Billion |
| 2007 | 24.41% | 17.31% | 0.75x | 1.87x | $6.24 Billion |
| 2008 | 30.46% | 20.31% | 0.75x | 2.00x | $8.70 Billion |
| 2009 | 24.25% | 19.82% | 0.65x | 1.87x | $7.21 Billion |
| 2010 | 23.57% | 21.65% | 0.60x | 1.82x | $7.68 Billion |
| 2011 | 16.94% | 14.87% | 0.57x | 1.99x | $3.96 Billion |
| 2012 | 16.74% | 16.14% | 0.55x | 1.87x | $4.37 Billion |
| 2013 | 18.68% | 19.40% | 0.54x | 1.79x | $6.43 Billion |
| 2014 | 23.40% | 21.96% | 0.57x | 1.87x | $9.35 Billion |
| 2015 | 21.66% | 21.99% | 0.53x | 1.88x | $8.29 Billion |
| 2016 | 23.49% | 23.01% | 0.51x | 2.01x | $9.50 Billion |
| 2017 | 2.16% | 1.70% | 0.49x | 2.61x | $-4.72 Billion |
| 2018 | 25.60% | 18.75% | 0.53x | 2.56x | $9.32 Billion |
| 2019 | 25.42% | 18.42% | 0.52x | 2.65x | $9.17 Billion |
| 2020 | 23.25% | 17.82% | 0.47x | 2.76x | $8.39 Billion |
| 2021 | 28.20% | 26.52% | 0.43x | 2.46x | $13.48 Billion |
| 2022 | 23.36% | 22.43% | 0.43x | 2.44x | $10.26 Billion |
| 2023 | 51.11% | 41.28% | 0.51x | 2.44x | $28.28 Billion |
| 2024 | 19.68% | 15.84% | 0.49x | 2.52x | $6.92 Billion |
Industry Comparison
This section compares Johnson & Johnson's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $355,057,678,100
- Average return on equity (ROE) among peers: -0.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $79.28 Billion | 18.31% | 1.43x | $572.79 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amgen Inc (AMGN) | $80.60 Million | 0.62% | 0.16x | $194.15 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |